Canbridge Pharmaceuticals (HKSE:01228) Other Current Receivables : HK$1.59 Mil (As of Dec. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Canbridge Pharmaceuticals Other Current Receivables?

Canbridge Pharmaceuticals's Other Current Receivables for the quarter that ended in Dec. 2024 was HK$1.59 Mil.

Canbridge Pharmaceuticals's quarterly Other Current Receivables increased from Dec. 2023 (HK$1.29 Mil) to Jun. 2024 (HK$12.89 Mil) but then stayed the same from Jun. 2024 (HK$12.89 Mil) to Dec. 2024 (HK$1.59 Mil).

Canbridge Pharmaceuticals's annual Other Current Receivables declined from Dec. 2022 (HK$14.71 Mil) to Dec. 2023 (HK$1.29 Mil) but then increased from Dec. 2023 (HK$1.29 Mil) to Dec. 2024 (HK$1.59 Mil).

Canbridge Pharmaceuticals Other Current Receivables Historical Data

The historical data trend for Canbridge Pharmaceuticals's Other Current Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Canbridge Pharmaceuticals Other Current Receivables Chart

Canbridge Pharmaceuticals Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Other Current Receivables

Get a 7-Day Free Trial

13.26

7.28

14.71

1.29

1.59

Canbridge Pharmaceuticals Semi-Annual Data
	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24	Dec24
Other Current Receivables	Get a 7-Day Free Trial						14.71	13.59	1.29	12.89	1.59

Canbridge Pharmaceuticals Other Current Receivables Calculation

GuruFocus uses a standardized financial statement format for all companies. GuruFocus lists Accounts Receivable, Notes Receivable , Loans Receivable and Other Current Receivables under the "Total Receivables" section.

Canbridge Pharmaceuticals Other Current Receivables Related Terms

Thank you for viewing the detailed overview of Canbridge Pharmaceuticals's Other Current Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.

Canbridge Pharmaceuticals Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Canbridge Pharmaceuticals Inc (HKSE:01228) » Definitions » Other Current Receivables

Comparable Companies

Traded in Other Exchanges

N/A

Address

No. 388 Xinping Street, Unit 18, 6th Floor, Building 21, Suzhou Industrial Park, Pilot Free Trade Zone, Jiangsu Province, Suzhou, CHN

Website

https://www.canbridgepharma.com

Canbridge Pharmaceuticals Inc is a biotechnology company committed to the research, development, and commercialization of biotech therapies targeting rare diseases and rare oncology. Its differentiated drug portfolio comprises both approved drugs and a pipeline of assets, targeting prevalent rare disease indications that have unmet needs and market potential. The group's approved products include Hunterase (CAN101) for the treatment of MPS II and Livmarli for the treatment of ALGS. The various other drug candidates in its development pipeline include CAN 103, CAN 107, CAN 104, CAN 105, and CAN 204, spanning biologics, small molecules, and gene therapy, targeting prevalent rare diseases and oncology indications. Geographically, it derives revenue from Chinese Mainland and other regions.

Executives

Qiming Corporate Gp Iv, Ltd.	2201 Interest of corporation controlled by you
Qiming Gp Iv, L.p.	2201 Interest of corporation controlled by you
Qiming Venture Partners Iv, L.p.	2101 Beneficial owner
Xue James Qun	2101 Beneficial owner
Jpmorgan Chase & Co.	2201 Interest of corporation controlled by you
Athos Capital Limited	2102 Investment manager
Moskey Matthew Love	2201 Interest of corporation controlled by you
Schulte-hillen Friedrich Bela	2201 Interest of corporation controlled by you
Athos Asia Event Driven Master Fund	2101 Beneficial owner
Ctx Pharma Holdings Limited	2101 Beneficial owner
Kolchinsky Anna Inge Leonore Haas	2202 Interest of your spouse
Kolchinsky Peter	2305 Beneficiary of a trust
Ra Capital Management, L.p.	2102 Investment manager
Ra Capital Healthcare Fund Gp, Llc	2201 Interest of corporation controlled by you
Ra Capital Healthcare Fund, L.p.	2101 Beneficial owner

Canbridge Pharmaceuticals Headlines

No Headlines